288 related articles for article (PubMed ID: 33865798)
1. Therapeutic Repurposing of Biguanides in Cancer.
Zhao H; Swanson KD; Zheng B
Trends Cancer; 2021 Aug; 7(8):714-730. PubMed ID: 33865798
[TBL] [Abstract][Full Text] [Related]
2. Serine deprivation enhances antineoplastic activity of biguanides.
Gravel SP; Hulea L; Toban N; Birman E; Blouin MJ; Zakikhani M; Zhao Y; Topisirovic I; St-Pierre J; Pollak M
Cancer Res; 2014 Dec; 74(24):7521-33. PubMed ID: 25377470
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Sáez-Martínez P; Gómez-Gómez E; León-González AJ; Fuentes-Fayos AC; Yubero-Serrano EM; Requena-Tapia MJ; López M; Castaño JP; Gahete MD; Luque RM
J Clin Endocrinol Metab; 2021 Jan; 106(2):e696-e710. PubMed ID: 33247590
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria.
Bridges HR; Jones AJ; Pollak MN; Hirst J
Biochem J; 2014 Sep; 462(3):475-87. PubMed ID: 25017630
[TBL] [Abstract][Full Text] [Related]
5. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.
Birsoy K; Possemato R; Lorbeer FK; Bayraktar EC; Thiru P; Yucel B; Wang T; Chen WW; Clish CB; Sabatini DM
Nature; 2014 Apr; 508(7494):108-12. PubMed ID: 24670634
[TBL] [Abstract][Full Text] [Related]
6. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
7. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.
Leone RD; Powell JD
Cancer Immunol Res; 2021 Mar; 9(3):255-260. PubMed ID: 33648947
[TBL] [Abstract][Full Text] [Related]
8. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
10. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
11. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
12. Metformin in breast cancer: preclinical and clinical evidence.
De A; Kuppusamy G
Curr Probl Cancer; 2020 Feb; 44(1):100488. PubMed ID: 31235186
[TBL] [Abstract][Full Text] [Related]
13. Potential applications for biguanides in oncology.
Pollak M
J Clin Invest; 2013 Sep; 123(9):3693-700. PubMed ID: 23999444
[TBL] [Abstract][Full Text] [Related]
14. Biguanides in combination with olaparib limits tumorigenesis of drug-resistant ovarian cancer cells through inhibition of Snail.
Wang Q; López-Ozuna VM; Baloch T; Bithras J; Amin O; Kessous R; Kogan L; Laskov I; Yasmeen A
Cancer Med; 2020 Feb; 9(4):1307-1320. PubMed ID: 31863638
[TBL] [Abstract][Full Text] [Related]
15. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
Wei Z; Zhang X; Yong T; Bie N; Zhan G; Li X; Liang Q; Li J; Yu J; Huang G; Yan Y; Zhang Z; Zhang B; Gan L; Huang B; Yang X
Nat Commun; 2021 Jan; 12(1):440. PubMed ID: 33469052
[TBL] [Abstract][Full Text] [Related]
16. Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides.
Hulea L; Gravel SP; Morita M; Cargnello M; Uchenunu O; Im YK; Lehuédé C; Ma EH; Leibovitch M; McLaughlan S; Blouin MJ; Parisotto M; Papavasiliou V; Lavoie C; Larsson O; Ohh M; Ferreira T; Greenwood C; Bridon G; Avizonis D; Ferbeyre G; Siegel P; Jones RG; Muller W; Ursini-Siegel J; St-Pierre J; Pollak M; Topisirovic I
Cell Metab; 2018 Dec; 28(6):817-832.e8. PubMed ID: 30244971
[TBL] [Abstract][Full Text] [Related]
17. Results from
Iversen AB; Horsman MR; Jakobsen S; Jensen JB; Garm C; Jessen N; Breining P; Frøkiær J; Busk M
Sci Rep; 2017 Aug; 7(1):9436. PubMed ID: 28842630
[TBL] [Abstract][Full Text] [Related]
18. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.
Orecchioni S; Reggiani F; Talarico G; Mancuso P; Calleri A; Gregato G; Labanca V; Noonan DM; Dallaglio K; Albini A; Bertolini F
Int J Cancer; 2015 Mar; 136(6):E534-44. PubMed ID: 25196138
[TBL] [Abstract][Full Text] [Related]
19. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
[TBL] [Abstract][Full Text] [Related]
20. Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors.
Xiao L; Yeung H; Haber M; Norris MD; Somers K
Trends Cancer; 2021 Aug; 7(8):751-777. PubMed ID: 34183305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
